Figure 6From: Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in VivoBreast sections of the different groups. A. Infiltrating ductal cancer in control group; B. Atypical hyperplasia in control group; C. Infiltrating ductal cancer in celecoxib group; D. Hyperplasia in celecoxib group (HE×200).Back to article page